Swan Capital’s Harmony Biosciences HRMY Stock Holding History

Swan Capital’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-36	Closed	-$1.44K	–	399
2024 Q3	$1.44K	Hold	36	–	–	﹤0.01%	242
2024 Q2	$1.09K	Buy	+36	New	+$1.08K	﹤0.01%	220

Other funds holding HRMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Swan Capital's HRMY Position: Q4 2024 in Review

Swan Capital sold out of Harmony Biosciences (HRMY) in Q4 2024, closing a stake of 36 shares — an estimated $1.44K sold.

Swan Capital first reported a position in HRMY in Q2 2024 and held it in 2 quarters. The position peaked at $1.44K in Q3 2024. 247 funds tracked by Wall St. Rank hold HRMY as of Q4 2024.

Swan Capital reported no remaining Harmony Biosciences position as of Q4 2024 after selling out during the quarter.
Swan Capital sold 36 Harmony Biosciences shares in Q4 2024, an estimated $1.44K.
Swan Capital first reported a position in Harmony Biosciences in Q2 2024 and held it in 2 quarters.
Swan Capital's Harmony Biosciences position peaked at $1.44K in Q3 2024.
247 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2024.

Based on Swan Capital's 13F filing for Q4 2024, filed 25 Feb 2025.